Welcome to our dedicated page for Core Scientific SEC filings (Ticker: CORZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Core Scientific, Inc. Tranche 2 Warrants (CORZZ) provides access to regulatory documents that explain how these warrants relate to Core Scientific’s common stock and broader capital structure. Core Scientific’s filings under the Exchange Act identify CORZZ as a class of warrants listed on the Nasdaq Global Select Market, each whole warrant exercisable for one share of Core Scientific common stock at a specified exercise price.
Through Forms 8-K and other filings, Core Scientific discloses material events affecting CORZZ, such as the satisfaction of trading price conditions that make tranche 2 warrants exercisable for a defined period. These filings describe the warrant terms, including exercise prices and the number of warrants outstanding, and may reference related press releases furnished as exhibits. Investors can review these documents to understand when and how CORZZ can be exercised and how many shares of common stock each warrant represents.
Filings also place CORZZ in the context of Core Scientific’s capital structure and corporate transactions. In connection with the company’s emergence from Chapter 11 reorganization, SEC disclosures outline the issuance of new common stock, tranche 1 warrants, tranche 2 warrants and other securities. Later 8-K filings describe an Agreement and Plan of Merger under which CoreWeave, Inc. is expected to acquire Core Scientific in an all-stock transaction. These documents explain how each share of Core Scientific common stock would convert into CoreWeave Class A common stock and how existing warrants, including tranche 2 warrants, would be adjusted into new warrants exercisable for CoreWeave shares based on an exchange ratio.
On Stock Titan, users can review real-time updates from EDGAR alongside AI-powered summaries that highlight key points from Core Scientific’s 8-Ks and other filings. These summaries help clarify the implications of warrant-related disclosures, merger terms, and other regulatory information without requiring readers to parse every technical detail. The filings page also surfaces information on registered securities, including CORZ, CORZW and CORZZ, so investors can see how the different instruments interact within Core Scientific’s disclosed capital structure.
Reporting persons G1 Execution Services, LLC; SIG Brokerage, LP; Susquehanna Investment Group; and Susquehanna Securities, LLC disclose an aggregate beneficial ownership of 18,336,176 shares of Core Scientific, Inc. common stock, representing 6.2% of the class based on the company’s reported 297,821,835 shares outstanding. The reported position includes direct holdings and securities exercisable or convertible into shares, including options and warrants.
The filing states these affiliated broker-dealers may be deemed a group and reports both sole and shared voting and dispositive power across the reporting persons. The reporting persons certify the holdings are held in the ordinary course of business and not for the purpose of changing control. Investors should note that part of the position derives from options, warrants or convertible instruments and therefore may reflect potential dilution rather than current free-floating shares.
Core Scientific reported a large headline net loss driven primarily by non-cash changes in derivative valuations, while its operating business shows mixed trends. Cash and cash equivalents declined to $581.3 million from $836.2 million, but the company materially increased its bitcoin holdings to 1,612 BTC with a fair value of $172.8 million. Total assets rose to $1.978 billion and property, plant and equipment, net increased to $828.6 million, reflecting ongoing capital investment.
Revenue fell versus prior year to $78.6 million for the quarter, producing a small gross profit but operating losses as selling, general and administrative costs rose. Large non-operating items included a $923.5 million increase in the fair value of Tranche 2 warrants recorded as expense, producing a three-month net loss of $936.8 million. Warrant liabilities total $1.3167 billion, convertible debt remains significant, and contractual capital commitments total approximately $1.71 billion. The company disclosed the proposed acquisition by CoreWeave and detailed related transaction risks.
Core Scientific, Inc. furnished a press release announcing its financial results for the second fiscal quarter ended June 30, 2025. The press release is provided as Exhibit 99.1 to this Current Report and is incorporated by reference into Items 2.02 and 7.01 of the filing. The company states that the information in Items 2.02 and 7.01, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference in Securities Act filings.
The 8-K itself does not include the underlying financial metrics or operational detail; readers must review Exhibit 99.1 for the actual results. The filing also lists the registrant's exchange-listed securities: common stock CORZ and warrants CORZW and CORZZ.
Two Seas Capital LP, together with its general partner and CIO Sina Toussi, filed a Schedule 13D disclosing beneficial ownership of 19,122,842 Core Scientific (CORZZ) shares, or 6.3 % of the outstanding common stock. The position is held across the firm’s Strategic Fund, Global Fund and two managed accounts and includes 5.72 m options and 313.6 k warrants. Aggregate consideration for the shares, options and warrants totals roughly $133.9 million, funded with the working capital of the funds/accounts.
The filing signals an activist stance: on 7 Aug 2025 Two Seas issued an open letter stating it will vote against the proposed merger between Core Scientific and CoreWeave and intends to solicit proxies opposing the deal at the forthcoming special meeting. The filer may engage management and other shareholders, and could adjust its exposure through additional purchases, sales or hedging transactions—including swaps that reference a notional 500 k shares—depending on market conditions and strategic considerations.